$RPRX

Revolution Medicines' pancreatic cancer drug, daraxonrasib, received FDA approval. Royalty Pharma, which invested in the drug, estimates peak revenues of $11 billion. Royalty Pharma could earn up to $340 million in royalties. The company has investments in 35 approved drugs, 16 of which are blockbusters. Royalty Pharma offers diversification and a 1.4% dividend yield.

Royalty Pharma acquired Zealand Pharma's royalty interest in Takeda's MIMRYLO for $100M, receiving 1% royalties on sales up to $1.5B and 0.75% above that. It also paid AstraZeneca $100M for a 3% royalty on ZORYVE sales. The company reported FDA approvals for RASONQUE and WELTRUZA, and positive phase III results for IMDELLTRA and deucrictibant XR. Royalty Pharma highlighted $1B in R&D co-funding deals, including a $500M agreement with Teva, and expansion in China.

Royalty Pharma reported 2026 revenue of $690.1M, up 13.3% YoY, but net income fell 49.1% to $144.68M and EPS declined 51.5% to $0.32. Total income for the first nine months rose 13.6% to $2.0B. The company made acquisitions and saw FDA approvals for Rasonque and Mimrylo, but faced setbacks with Pelacarsen and Tazverik.

Royalty Pharma reported Q3 2026 Portfolio Receipts of $890M, up 9% YoY, and raised full-year guidance to $3.50B-$3.55B. Operating income was $411M, down from $427M in Q3 2025. Receipts growth was driven by therapies like Tremfya and Voranigo. The company acquired royalty interests in Zoryve and Mimrylo for $100M each and recorded a $150M impairment charge for pelacarsen.

Royalty Pharma plc (RPRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Press Release November 4, 2026 R oyalty Pharma reports third quarter 2026 results Portfolio Rece ipts growth o f 9% to $890 million ; Royalty Receipts growth of 9% Net cash provided by operating activities of $686 million Raised full year 2026 guidance: Portfolio Receipts expecte

Royalty Pharma (RPRX) declared a Q4 2026 dividend of $0.235 per share, payable Dec. 10, 2026, to shareholders of record by Nov. 13, 2026. The company acquires biopharmaceutical royalties and funds biopharma development, with a portfolio of 35+ commercial products and 16 development-stage candidates.

Royalty Pharma (RPRX) will release its Q3 2026 financial results on November 4, 2026, before market open, followed by a conference call and webcast. The company is a major buyer of biopharmaceutical royalties, with a portfolio including royalties on over 35 commercial products and 17 development-stage candidates. Investors can access the call details and webcast on the company's website.

Royalty Pharma's EVP Christopher Hite sold 100,000 shares worth $5.85m on September 22, 2026, under a 10b5-1 plan. He now holds 23,200 shares directly and 270,401 indirectly. Royalty Pharma's stock has risen 70% in the past year, with a market cap of $33.5bn and P/E ratio of 31.3. The company reported Q2 2026 revenue of $768m, up 14%, and raised its 2026 outlook. Analysts BofA and TD Cowen raised price targets to $63 and $68, respectively.

Revolution Medicines (RVMD) received FDA breakthrough therapy designation for its pancreatic cancer drug, RASONQUE. The stock has surged 330% in a year. Royalty Pharma (RPRX) offers diversified exposure to RVMD and other drugs, with a 1.6% dividend yield. RPRX is up 60% in a year, providing a balanced risk-reward option.

Hite Christopher (EVP & Chairman, Partnering) sold 100,000 indirectly-held shares of Royalty Pharma plc (RPRX) at an average of $58.53 ($58.51–$58.93, $5.85M total) across 2 trades on 2026-09-22 under a Rule 10b5-1 trading plan.